Download PDF
Pharmacopsychiatry 2008; 41: S51-S59
DOI: 10.1055/s-2008-1081463
Review

© Georg Thieme Verlag KG Stuttgart · New York

The Molecular and Cellular Neurobiology of Nicotine Abuse in Schizophrenia

A. Mobascher 1 , G. Winterer 1
  • 1Department of Psychiatry, Heinrich-Heine-University, Duesseldorf, Germany
Further Information

Publication History

Publication Date:
28 August 2008 (online)

Also available at
    Permissions and Reprints

Abstract

People with schizophrenia suffer from a variety of symptoms that can be categorized as positive, negative and cognitive symptoms. Cognitive symptoms are not properly treated with antipsychotic medication and are the major cause of disability associated with the disorder. People with schizophrenia smoke more frequently and heavily than the general population. This observation in view of the well established role of nicotinic, cholinergic neurotransmission in cognition led to the hypothesis that people with schizophrenia may use nicotine as a self-medication to ameliorate cognitive symptoms associated with their disease. Furthermore genetic and post-mortem studies point to additional links between nicotinic cholinergic neurotransmission and schizophrenia. This article provides an insight in the possible relationship between schizophrenia and smoking behavior. We focus on the effects of nicotine on individual neurons as well as on neuronal networks. With respect to single neurons the immediate electrophysiological consequences of nicotinic stimulation and the more “metabotropic” effects related to intracellular signal transduction cascades that may lead to plastic changes in the neuron are discussed. With respect to the network level, three systems are discussed: cognition, reward and stress response. The effects of nicotine on cognition may be most pertinent to the problem of schizophrenia, but schizophrenics may also smoke to regulate mood and reduce stress. A better understanding of the molecular and cellular effects of nicotine and how they are related to the pathophysiology and symptomatology of schizophrenia may help to identify new targets for the pharmacotherapy of schizophrenia and of nicotine addiction in schizophrenia.

References

  • 1 Adams CE, Stevens KE. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia.  Front Biosci. 2007;  12 4755-4772
    CrossrefPubMedGoogle Scholar
  • 2 Addington J. Group treatment for smoking cessation among persons with schizophrenia.  Psychiatr Serv. 1998;  49 925-928
    PubMedGoogle Scholar
  • 3 Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients.  Am J Psychiatry. 1993;  150 1856-1861
    PubMedGoogle Scholar
  • 4 Al Abisi M. Hypothalamic-pituitary-adrenocortical responses to psychological stress and risk for smoking relapse.  Int J Psychophysiol. 2006;  59 218-227
    CrossrefPubMedGoogle Scholar
  • 5 Andreas S, Loddenkemper R. Tabakprävention.  Pulmonologie und Intensivmedizin. 2008;  , in press
    PubMedGoogle Scholar
  • 6 Balfour DJK, Wright AE, Benwell MEM, Birrell CE. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence.  Behav Brain Res. 2000;  113 73-83
    CrossrefPubMedGoogle Scholar
  • 7 Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, Gainetdinov Raul R, Borrelli E, Caron MG. Regulation of Akt signalling by D2 and D3 dopamine receptors in vivo.  J Neurosci. 2007;  27 881-885
    CrossrefPubMedGoogle Scholar
  • 8 Bender W, Albus M, Möller HJ, Tretter F. Towards systemic theories in biological psychiatry.  Pharmacopsychiatry. 2006;  39 ((Suppl 1)) 4-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Besson M, Granon S, Mameli-Engvall M, Cloez-Tayarani I, Maubourguet N, Cormier A, Cazala P, David V, Changeux JP, Faure P. Long-term effects of chronic nicotine exposure on brain nicotinic receptors.  PNAS. 2007;  104 8155-8160
    CrossrefPubMedGoogle Scholar
  • 10 Bilkei-Gorzo A, Racz I, Michel K, Darvas M, Maldonado R, Zimmer A. A common genetic predisposition to stress sensitivity and stress-induced nicotine craving.  Biol Psychiatry. 2007;  , in press
    PubMedGoogle Scholar
  • 11 Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, Li J, Malysz J, Markosyan S, Marsh K, Meyer MD, Nikkel AL, Radek RJ, Robb HM, Timmermann D, Sullivan JP, Gopalakrishnan M. Broad-sprectrum efficacy, across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK 1/2 and CREB phosphorylation pathways.  J Neurosci. 2007;  27 10578-10587
    CrossrefPubMedGoogle Scholar
  • 12 Breslau N, Johnson EO. Predicting smoking cessation and major depression in nicotine-dependent smokers.  Am J Public Health. 2000;  90 1122-1127
    CrossrefPubMedGoogle Scholar
  • 13 Breslau N, Kilbey MM, Andreski P. Nicotine dependence and major depression. New evidence form a prospective investigation.  Arch Gen Psychiatry. 1993;  50 31-35
    PubMedGoogle Scholar
  • 14 Cardenas L, Tremblay LK, Naranjo CA, Herrmann N, Zack M, Busto UE. Brain reward system activity in major depression and comorbid nicotine dependence.  J Pharmacol Exp Ther. 2002;  302 1265-1271
    CrossrefPubMedGoogle Scholar
  • 15 Cattapan-Ludewig K, Ludewig S, Jaquenoud Sirot E, Etzensberger M, Hasler F. Why do schizophrenic patients smoke?.  Nervenarzt. 2005;  76 287-294
    CrossrefPubMedGoogle Scholar
  • 16 Chen L, Bohanick JD, Nishihara M, Seamans JK, Yang CR. Dopamin D1/D5 receptor-mediated long-term potentiation of intrinsic excitability in rat prefrontal cortical neurons: Ca++-dependent intracellular signalling.  J Neurophysiol. 2007;  97 2448-2464
    CrossrefPubMedGoogle Scholar
  • 17 Couey JJ, Meredith RM, Spijker S, Poorthuis RB, Smit AB, Brussaard AB, Mansvelder HD. Distributed network actions by nicotine increase the threshold for spike-timing dependent plasticity in prefrontal cortex.  Neuron. 2007;  54 73-87
    CrossrefPubMedGoogle Scholar
  • 18 Dani JA, Biasi M De. Cellular mechanisms of nicotine addiction.  Pharmacology, Biochemistry and Behavior. 2001;  70 439-446
    CrossrefPubMedGoogle Scholar
  • 19 Leon J de, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital.  Am J Psychiatry. 1995;  152 453-455
    PubMedGoogle Scholar
  • 20 Chiara G Di, Bassareo V, Fenu S, Luca MA De, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection.  Neuropharmacol. 2004;  47 227-241
    CrossrefPubMedGoogle Scholar
  • 21 Durany N, Zöchlinger R, Boissl KW, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Deckert J, Riederer P. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome.  Neurosci Lett. 2000;  287 109-112
    CrossrefPubMedGoogle Scholar
  • 22 Edwards JA, Wesnes K, Warburton DM, Gale A. Evidence of more rapid stimulus evaluation following cigarette smoking.  Addict Behav. 1985;  10 113-126
    CrossrefPubMedGoogle Scholar
  • 23 Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired Akt1-GSK3beta signaling in schizophrenia.  Nat Genet. 2004;  36 131-137
    PubMedGoogle Scholar
  • 24 Fagen ZM, Mitchum R, Vezina P, MacGehee DS. Enhanced nicotinic receptor function and drug abuse vulnerability.  J Neurosci. 2007;  27 8771-8778
    CrossrefPubMedGoogle Scholar
  • 25 Ferrari R, Le Novere N, Picciotto MR, Changeux JP, Zoli M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections.  Eur J Neurosci. 2002;  15 1810-1818
    CrossrefPubMedGoogle Scholar
  • 26 Fischbach GD. NRG1 and synaptic function in the CNS.  Neuron. 2007;  54 495-497
    CrossrefPubMedGoogle Scholar
  • 27 Freedman R, Hall M, Adler LE, Leonard S. Evidence in post-mortem brain tissue for decreased number of hippocampal nicotinic receptors in schizophrenia.  Biol Psychiatry. 1995;  38 22-33
    CrossrefPubMedGoogle Scholar
  • 28 Freedman R, Adams CE, Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia.  J Chem Neuroanat. 2000;  20 299-306
    CrossrefPubMedGoogle Scholar
  • 29 Fuxe K, Andersson K, Eneroth P, Harfstrand A, Agnati LF. Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications.  Psychoneuroendocrinology. 1989;  14 19-41
    CrossrefPubMedGoogle Scholar
  • 30 Fujii S, Ji Z, Morita N, Sumikawa K. Acute and chronic nicotine exposure differentially facilitate the induction of LTP.  Brain Res. 1999;  846 137-143
    CrossrefPubMedGoogle Scholar
  • 31 Gallinat J, Obermayer K, Heinz A. Systems neurobiology of the dysfunctional brain: Schizophrenia.  Pharmacopsychiatry. 2007;  40 ((Suppl 1)) 40-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Gallinat J, Heinz A. Combination of multimodal imaging and molecular genetic information to investigate complex psychiatric disorders.  Pharmacopsychiatry. 2006;  39 ((Suppl 1)) 76-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Ge S, Dani JA. Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation.  J Neurosci. 2005;  25 6084-6091
    CrossrefPubMedGoogle Scholar
  • 34 Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial.  JAMA. 1988;  259 2863-2866
    CrossrefPubMedGoogle Scholar
  • 35 Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance.  Trends Pharmacol Sci. 2006;  27 482-491
    CrossrefPubMedGoogle Scholar
  • 36 Hahn B, Ross TJ, Yang Y, Kim I, Huestis MA, Stein EA. Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network.  J Neurosci. 2007;  27 3477-3489
    CrossrefPubMedGoogle Scholar
  • 37 Hahn B, Sharples CG, Wonnacott S, Shoaib M, Stolerman IP. Attentional effects of nicotinic agonists in rats.  Neurophyrmacology. 2003;  44 1054-1067
    CrossrefPubMedGoogle Scholar
  • 38 Hahn B, Shoaib M, Stolerman IP. Nicotine-induced enhancement of attention in the five-choice serial reaction time task. The influence of task demands.  Psychopharmacology (Berl). 2002;  162 129-137
    CrossrefPubMedGoogle Scholar
  • 39 Haro R, Drucker-Colin R. A two-year study on the effects of nicotine and its withdrawal on mood and sleep.  Pharmacopsychiatry. 2004;  37 221-227
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, Zerbe G, Freedman R. Effects of nicotine on cognitive deficits in schizophrenia.  Neuropsychopharmacology. 2004;  29 1378-1385
    CrossrefPubMedGoogle Scholar
  • 41 Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression and neuropathology: on the matter of their convergence.  Mol Psychiatry. 2005;  10 40-68
    CrossrefPubMedGoogle Scholar
  • 42 Heinz A, Schmidt LG, Reischies FM. Anhedonia in schizophrenic, depressed and alcohol-dependent patients – neurobiological correlates.  Pharmacopsychiatry. 1994;  27 ((Suppl. 1)) 7-10
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia.  J Clin Psychiatry. 2007;  68 ((Suppl 4)) 4-7
    CrossrefPubMedGoogle Scholar
  • 44 Houlihan ME, Pritchard WS, Krieble KK, Robinson JH, Duke DW. Effects of cigarette smoking on EEG spectral-band power, dimensional complexity, and nonlinearity during reaction time task performance.  Psychophysiology. 1996a;  33 740-746
    CrossrefPubMedGoogle Scholar
  • 45 Houlihan ME, Pritchard WS, Robinson JH. Faster P300 latency after smoking in visual but not auditory oddball tasks.  Psychopharmacology. 1996b;  123 231-238
    CrossrefPubMedGoogle Scholar
  • 46 Ikemoto S. Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens – olfactory tubercle complex.  Brain Res Rev. 2007;  , in press
    PubMedGoogle Scholar
  • 47 Inoue Y, Yao L, Hopf W, Fan P, Jiang Z, Bronci A, Diamond I. Nicotine and ethanol activate protein kinase A synergistically via Gißγ subunits in nucleus acumbens/ventral tegmental cocultures: The role of dopamine D1/D2 and adenosine A2A receptors.  J Pharmacol Exp Ther. 2007;  322 23-29
    CrossrefPubMedGoogle Scholar
  • 48 Javitt DC. Treatment of negative and cognitive symptoms.  Curr Psychiatry Rep. 1999;  1 25-30
    CrossrefPubMedGoogle Scholar
  • 49 Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity.  Neuron. 2001;  31 131-141
    CrossrefPubMedGoogle Scholar
  • 50 Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric disease and therapeutic interventions.  Curr Drug Targets. 2006;  7 1421-1434
    PubMedGoogle Scholar
  • 51 Juckel G, Sass L, Heinz A. Anhedonia, self-experience in schizophrenia, and implications for treatment.  Pharmacopsychiatry. 2003;  36 ((Suppl 3)) 176-180
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Kanakry CG, Li Z, Nakai Y, Sei Y, Weinberger DR. Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer.  PLoS One. 2007;  2 ((12)) e1369
    CrossrefPubMedGoogle Scholar
  • 53 Kelleher RJ, Govindarajan A, Tonegawa S. Translational regulatory mechanisms in persistent forms of synaptic plasticity.  Neuron. 2004;  44 59-73
    CrossrefPubMedGoogle Scholar
  • 54 Keuthen NJ, Niaura RS, Borrelli B, Goldstein M, DePue J, Murphy C, Gastfriend D, Reiter SR, Abrams D. Comorbidity, smoking behavior and treatment outcome.  Psychother Psychosom. 2000;  69 244-250
    CrossrefPubMedGoogle Scholar
  • 55 Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaide A. 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A ß-amyloid-induced neurotoxicity.  J Biol Chem. 2001;  276 13541-13546
    PubMedGoogle Scholar
  • 56 Kwon OB, Longart M, Vullhorst D, Hoffman DA, Buonanno A. Neuregulin-1 reverses long-term potentiation at Ca1 hippocampal synapses.  J Neurosci. 2005;  25 9378-9383
    CrossrefPubMedGoogle Scholar
  • 57 Lang UE, Puls I, Müller DJ, Strutz-Seebohm Gallinat J. Molecular mechanisms of schizophrenia.  Cell Phys Biochem. 2007;  20 687-702
    PubMedGoogle Scholar
  • 58 Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, MacCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study.  JAMA. 2000;  284 2606-2610
    CrossrefPubMedGoogle Scholar
  • 59 Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, MacCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study.  JAMA. 2000;  284 2606-2610
    CrossrefPubMedGoogle Scholar
  • 60 Lawrence NS, Ross TJ, Stein EA. Cognitive mechanisms of nicotine on visual attention.  Neuron. 2002;  36 539-548
    CrossrefPubMedGoogle Scholar
  • 61 Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P. Association of promoter variants in the alpha 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.  Arch Gen Psychiatry. 2002;  59 1085-1096
    CrossrefPubMedGoogle Scholar
  • 62 Levin ED, MacClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification and anatomical localization.  Psychopharmacol. 2006;  184 523-439
    PubMedGoogle Scholar
  • 63 Levine Conners CK, Silva D, Canu W, March J. Effects of chronic nicotine and methylphenidate in adults with ADHD.  Exp Clin Pharmacol. 2001;  9 83-90
    PubMedGoogle Scholar
  • 64 Levine ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder.  Psychopharmacology (Berin). 1996;  123 55-63
    CrossrefPubMedGoogle Scholar
  • 65 Li B, Woo RS, Mei L, Malinow R. The neuregulin-1 receptor ErbB4 controls glutamatergic synapse maturation and plasticity.  Neuron. 2007;  54 583-597
    CrossrefPubMedGoogle Scholar
  • 66 LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy.  Anticancer Drugs. 2007;  18 861-874
    PubMedGoogle Scholar
  • 67 Lovallo WR. Cortisol secretion patterns in addiction and addiction risk.  Int J Psychpharmacol. 2006;  59 195-202
    PubMedGoogle Scholar
  • 68 Matta SG, Fu Y, Valentine JD, Sharp BM. Response of the hypothalamo-pituitary-adrenalo axis to nicotine.  Psychoneuroendocrinology. 1998;  23 103-113
    CrossrefPubMedGoogle Scholar
  • 69 Manning BD, Cantley LC. Akt/PKB signalling: navigating downstream.  Cell. 2007;  129 1261-1274
    CrossrefPubMedGoogle Scholar
  • 70 Mann EO, Greenfield SA. Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro.  J Physiol. 2003;  551 539-550
    CrossrefPubMedGoogle Scholar
  • 71 Mansvelder HD, Aerde KI van, Couey JJ, Brussaard AB. Nicotinic modulation of neuronal networks: from receptors to cognition.  Psychopharmacol. 2006;  184 292-305
    PubMedGoogle Scholar
  • 72 Mansvelder HD, MacGee DS. Long-term potentiation of excita-tory inputs to brain reward areas by nicotine.  Neuron. 2000;  27 349-357
    CrossrefPubMedGoogle Scholar
  • 73 Mansvelder H, Keath JR, MacGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas.  Neuron. 2002;  33 905-919
    CrossrefPubMedGoogle Scholar
  • 74 MacGehee DS. Nicotine and synaptic plasticity in the prefrontal cortex.  Sci STKE. 2007;  pe44
    CrossrefPubMedGoogle Scholar
  • 75 Meisenzahl EM, Scheuerecker J, Schmitt GJ, Möller HJ. Dopamine, prefrontal cortex and working memory functioning in schizophrenia.  Pharmacopsychiatry. 2007;  40 ((Suppl 1)) 62-72
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Mineur YS, Picciotto MR. Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction.  Biochem Pharmacol. 2007;  75 323-333
    PubMedGoogle Scholar
  • 77 Musso F, Bettermann F, Vucurevic G, Stoeter P, Konrad A, Winterer G. Smoking impacts on prefrontal attention network function in young adult brains.  Psychopharmacology. 2007;  191 159-169
    CrossrefPubMedGoogle Scholar
  • 78 Nakayama H, Numakawa T, Ikeuchi T, Hatanaka H. Nicotine-induced phosphorylation of extracellular signal-regulated protein kinase and CREB in PC12 h cells.  J Neurochem. 2001;  79 489-498
    CrossrefPubMedGoogle Scholar
  • 79 Ohno M, Yamamoto T, Watanabe S. Blockade of hippocampal nicotinic receptors impairs working memory but not reference memory in rats.  Pharmacol Biochem Behav. 1993;  45 89-93
    CrossrefPubMedGoogle Scholar
  • 80 Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Boushcet T, Matthews P, Isaac JTR, Bortolotto ZA, Wang YT, Collingridge GL. LTP inhibits LTD in the hippocampus via regulation of GSK3ß.  Neuron. 2007;  53 703-717
    CrossrefPubMedGoogle Scholar
  • 81 Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover.  Mol Pharmacol. 1994;  46 523-530
    PubMedGoogle Scholar
  • 82 Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons.  Nature. 1997;  390 401-404
    CrossrefPubMedGoogle Scholar
  • 83 Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder.  J Subst Abuse. 1995;  7 373-378
    CrossrefPubMedGoogle Scholar
  • 84 Rohleder N, Kirschbaum C. The hypothalamic-pituitary-adrenal (HPA) axis in habitual smokers.  Int J Psychphysiol. 2006;  59 236-243
    PubMedGoogle Scholar
  • 85 Raymond CR. LTP forms 1, 2 and 3: different mechanism for the “long” in long-term potentiation.  Trends in Neurosci. 2007;  30 167-175
    PubMedGoogle Scholar
  • 86 Rezvani K, Teng Y, Shim D, Biasi M De. Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity.  J Neurosci. 2007;  27 10508-10519
    CrossrefPubMedGoogle Scholar
  • 87 Rezvani AH, Levin ED. Cognitive effects of nicotine.  Biol Psychiatry. 2001;  49 258-167
    CrossrefPubMedGoogle Scholar
  • 88 Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.  Oncogene. 2007;  26 3291-3210
    CrossrefPubMedGoogle Scholar
  • 89 Robinson SE, Vann RE, Britton AF, O’Connell MM, James JR, Rosecrans JA. Cellular nicotinic receptor desensitization correlates with nicotine-induced acute behavioural tolerance in rats.  Psychopharmacology. 2007;  192 71-78
    CrossrefPubMedGoogle Scholar
  • 90 Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.  J Psychopharmacol. 2004;  18 457-474
    CrossrefPubMedGoogle Scholar
  • 91 Sallette J, Pons S, Devillers-Thiery A, Soudant M, Prado de Carvalho L, Changeux JP, Corringer PJ. Nicotine upregulates its own recep-tors through enhanced intracellular maturation.  Neuron. 2005;  46 595-607
    CrossrefPubMedGoogle Scholar
  • 92 Schmitt JM, Guire ES, Saneyoshi T, Soderling TR. Calmodulin-dependent kinase kinase/calmodulin kinase I activity gates extracellular-regulated kinase-dependent long-term potentiation.  J Neurosci. 2005;  25 1281-1290
    CrossrefPubMedGoogle Scholar
  • 93 Sherwood N, Kerr JS, Hindmarch I. Psychomotor performance in smokers following single and repeated doses of nicotine gum.  Psychopharmacology (Berlin). 1992;  108 432-436
    CrossrefPubMedGoogle Scholar
  • 94 Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia.  Neuropsychopharmacology. 2002;  27 479-497
    CrossrefPubMedGoogle Scholar
  • 95 Staley JK, Krishnan-Sarin S, Kelly P, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR, London ED, O’Malley S, Dyck CH van. Human tobacco smokers in early abstinence have higher levels of ß2* nicotinic acetylcholine receptors than nonsmokers.  J Neurosci. 2006;  26 8707-8714
    CrossrefPubMedGoogle Scholar
  • 96 Steiner RC, Heath CJ, Picciotto MR. Nicotine-induced phosphorylation of ERK in mouse primary cortical neurons: evidence for involvement of glutamatergic signalling and CaMKII.  J Neurochem. 2007;  103 666-678
    CrossrefPubMedGoogle Scholar
  • 97 Stolerman IP, Mirza NR, Hahn B, Shoaib M. Nicotine in an animal model of attention.  Eur J Pharmacol. 2000;  393 147-154
    CrossrefPubMedGoogle Scholar
  • 98 Sugano T, Yanagita T, Yokoo H, Satoh S, Kobayashi H, Wada A. Enhancement of insulin-induced PI3K/Akt/GSK-3ß and ERK signalling by neuronal nicotinic receptor/ PKC-α/ERK pathway: upregulation of IRS-1/-2 mRNA and protein in adrenal chromaffin cells.  J Neurochem. 2006;  98 20-33
    CrossrefPubMedGoogle Scholar
  • 99 Thiel CM, Zilles K, Fink GR. Nicotine modulates reorienting of visuospatial attention and neural activity in human parietal cortex.  Neuropsychopharmacology. 2005;  30 810-820
    PubMedGoogle Scholar
  • 100 Thorndike FP, Wernicke R, Pearlman MY, Haaga DAF. Nicotine dependence.  PTSD symptoms and depression proneness among male and female smokers Addict Behav. 2006;  31 223-231
    CrossrefPubMedGoogle Scholar
  • 101 Tretter F, Albus M. “Computational neuropsychiatry” of working memory disorders in schizophrenia: the network connectivity in prefrontal cortex – data and models.  Pharmacopsychiatry. 2007;  40 ((Suppl 1)) 2-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 102 Tretter F, Scherer J. Schizophrenia, neurobiology and the methodology of systemic modeling.  Pharmacopsychiatry. 2006;  39 ((Suppl 1)) 26-35
    Article in Thieme ConnectPubMedGoogle Scholar
  • 103 Heide LP van der, Ramakers GMJ, Smidt MP. Insulin signaling in the central nervous system: Learning to survive.  Progress in Neurobiology. 2006;  79 205-221
    CrossrefPubMedGoogle Scholar
  • 104 Wang Q, Liu L, Pei L, Ju W, Ahmadian G, Lu J, Wang Y, Liu F, Wang YT. Control of synaptic strength, a novel function of Akt.  Neuron. 2003;  38 915-928
    CrossrefPubMedGoogle Scholar
  • 105 Weeber EJ, Sweatt JD. Molecular neurobiology of human cognition.  Neuron. 2002;  845-848
    CrossrefPubMedGoogle Scholar
  • 106 Weinberger DR, Gallhofer B. Cognitive function in schizophrenia.  Int Clin Psychopharmacol. 1997;  12 ((Suppl 4)) 29-36
    PubMedGoogle Scholar
  • 107 Wesnes K, Warburton DM. Effects of smoking on rapid information processing performance.  Neuropsychobiology. 1983;  9 223-229
    CrossrefPubMedGoogle Scholar
  • 108 Winterer G, Weinberger DR. Genes, dopamine and cortical signal to noise ratio in schizophrenia.  Trends Neurosci. 2004;  27 683-690
    CrossrefPubMedGoogle Scholar
  • 109 Winterer G, Coppola R, Goldberg T, Egan M, Jones D, Sanchez CE, Weinberger DR. Prefrontal broadband noise, working memory and genetic risk for schizophrenia.  Am J Psychiatry. 2004;  161 490-500
    CrossrefPubMedGoogle Scholar
  • 110 Winterer G, Musso F, Beckmann C, Mattay V, Egan MF, Jones DW, Callicot JH, Coppola R, Weinberger DR. Instability of prefrontal signal processing in schizophrenia.  Am J Psychiatry. 2006a;  163 1960-1968
    CrossrefPubMedGoogle Scholar
  • 111 Winterer G, Egan MF, Kolachana BS, Goldberg TE, Coppola R, Weinberger DR. Prefrontal electrophysiologic “noise” and catechol-O-methyltransferase genotype in schizophrenia.  Biol Psychiatry. 2006b;  60 578-584
    CrossrefPubMedGoogle Scholar
  • 112 Winterer G. Cortical microcircuits in schizophrenia – the dopamine hypothesis revisited.  Pharmacopsychiatry. 2006c;  39 ((Suppl 1)) 68-71
    Article in Thieme ConnectPubMedGoogle Scholar
  • 113 Winterer G. Proefrontal dopamine signaling in schizophrenia – the corticocentric model.  Pharmacopsychiatry. 2007;  40 ((Suppl 1)) 45-53
    Article in Thieme ConnectPubMedGoogle Scholar
  • 114 Wonnacott S, Sidhpura N, Balfour DJK. Nicotine: from molecular mechanisms to behaviour.  Current Opin Pharmacol. 2005;  5 53-59
    PubMedGoogle Scholar
  • 115 Woo RS, Li XM, Tao Y, Carpenter-Hyland E, Huang YZ, Weber J, Neiswender H, Dong XP, Wu J, Gassmann M, Lai C, Xiong WC, Gao TM, Mei L. Neuregulin-1 enhances depolarization-induced GABA release.  Neuron. 2007;  54 599-610
    CrossrefPubMedGoogle Scholar
  • 116 Yoshii A, Constantine-Paton M. BNDF induces transport of PSD-95 to dendrites through PI3K-Akt signalling aftrer NMDA receptor activation.  Nature Neurosci. 2007;  10 702-711
    CrossrefPubMedGoogle Scholar

Correspondence

Prof. Dr. G. Winterer

Department of Psychiatry

Heinrich-Heine-University

Bergische Landstr. 2

40629 Duesseldorf

Germany

Email: georg.winterer@uni-duesseldorf.de

      >